<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958775</url>
  </required_header>
  <id_info>
    <org_study_id>REB-07-0394</org_study_id>
    <nct_id>NCT01958775</nct_id>
  </id_info>
  <brief_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2</brief_title>
  <official_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study
           A)

        2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study A: Using constant feeding with a nasoduodenal tube and stable isotope infusion,
      mathematical modelling will be utilised to measure lipoprotein production and clearance. The
      lipoproteins assessed will be apoB-100 from the liver and apoB-48 from the intestine.

      StudyB: Volunteers will be given a liquid meal with retinyl palmitate (vitamin A) to label
      chylomicrons made from the meal. 7 hours later they will be given GLP-2 or placebo.
      Measurements of plasma and TRL(triglyceride rich lipoprotein) triglyceride and TRL retinyl
      palmitate will be carried out to see whether GLP-2 increases these parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoprotein production and clearance rate</measure>
    <time_frame>10 hours</time_frame>
    <description>ApoB 100 and ApoB 48 production and clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and TRL triglyceride and TRL retinyl palmitate</measure>
    <time_frame>10 hours</time_frame>
    <description>Measurements will be carried out hourly after ingestion of meal and then every 15-30 minutes thereafter to see if GLP-2 increases these parameters compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>GLP=2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with a single dose of GLP-2 (1500mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>single subcutaneous dose of 1500mcg</description>
    <arm_group_label>GLP=2</arm_group_label>
    <other_name>glucagon like peptide 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria:

               1. Men and women, aged 18 to 60 years

               2. Body mass index 20 kg/m2 to 30 kg/m2

               3. Hemoglobin above 130g/L.

               4. Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test
                  (OGTT)

        Exclusion Criteria:

          -  1. Subject has a history of hepatitis/hepatic disease that has been active within the
             previous two years.

             2. Any significant active (over the past 12 months) disease of the gastrointestinal,
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL), genitourinary, hematological systems,
             or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP &gt;
             100 or systolic &gt; 180) or proliferative retinopathy 3. History of diabetes or OGTT
             indicative of diabetes or impaired glucose tolerance.

             4. Any history of ischemic heart disease or clinically significant, active,
             cardiovascular history including a history of arrhythmia's or conduction delays on
             ECG, unstable angina, or decompensated heart failure.

             5. Abnormal liver or thyroid function tests 6. Current addiction to alcohol or
             substances of abuse as determined by the investigator.

             7. Mental incapacity, unwillingness or language barrier precluding adequate
             understanding or cooperation 8. Taking any prescription or non-prescription
             medications at the time of the study 9. Having donated blood three months prior to and
             three months post study procedures 10. A pregnancy test will be performed 1 to 3 days
             prior to each study in all female research participants. Those who test positive for
             pregnancy will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoproteins, apoB, GLP-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

